Vinmec performs its first total femoral replacement for world's youngest cancer patient
Vinmec successfully performs world's youngest pediatric total femur replacement surgery using 3D printing technology.
HANOI, VIETNAM - Media OutReach Newswire - 11 June 2025 -In October 2022, after a minor fall, Tran Minh Duc (a boy from Ho Chi Minh City) hurt his left thigh. Believing it to be just a simple injury, his family was shocked to hear the bad news from the doctor: The boy was diagnosed with osteosarcoma - a malignant bone cancer with a tumor that had invaded his entire femur. It is typically seen in adolescents, but rare and haphazard in younger children.Given the severe prognosis, most medical facilities recommended amputation to ensure his survival or bone grafting (a conventional method). Both methods carry a high risk of rejection and infection, especially for younger children in the development stage.The flash of hope appeared when she met Prof. Dr. Tran Trung Dung - Director of the Orthopedic Council, Vinmec Healthcare System. An unprecedented approach was proposed to apply to such a young patient:According to Prof. Dr. Tran Trung Dung, the entire femur of Duc has been invaded by the tumor. To ensure his life, Duc's leg had to be amputated. However, different types of artificial joints available on the market are not compatible with young bodies.After various interdisciplinary case conferences including Orthopedics, Oncology, Diagnostic Imaging, Pathology, Clinical Pharmacy, etc., the Vinmec experts reached a consensus on the optimal approach - a two-phase surgery. Phase 1 (January 2024): Removing the tumor and temporarily grafting a cement bone. Phase 2 (May 2025): Replacing the entire femur with a "customized" bone made of 3D-printed metal.On January 29, 2024, Duc underwent his first surgery - removing the entire tumor and temporarily grafting a cement bone. In May 2025 when his conditions had stabilized, Duc's entire femur was replaced with a "customized" bone made of 3D-printed metal. For the first time, 3D printing was applied to the youngest patient in the world with the collaboration between Vinmec medical professionals and VinUni's engineers. The bone's design is modular, enabling future extensions based on the child's physical development.According to MSc. Dr. Tran Duc Thanh, who was directly engaged in the surgery:Prof. Dr. Tran Trung Dung added: "The 4-hour surgery was a success. Duc recovered quickly without any complications, now he is able to walk with the support of physical therapy. The surgery represented a breakthrough in complex techniques and the evidence for sound collaboration in the multidisciplinary medical team. Both the life and limb of the child were kept intact."Once at risk of amputation and life-long dependence, Minh Duc is now able to walk on his own feet, supported by physical therapy without any complications of infection or transplant rejection. Every step Duc takes is a testament to precision medicine, advanced technologies, and the unwavering love of his mother.- Ms. Hoang said in tears.Prof. Dr. Tran Trung Dung also shared his emotions:Vinmec is the first Vietnamese healthcare system that applies personalized 3D printing in the treatment of musculoskeletal conditions. Instead of using standardized equipment, Vinmec uses CT and MRI data in the design of artificial joints and bones tailored to each patient to optimize motor functions, enhance precision, and reduce the recovery period.To date, Vinmec has achieved successes in many difficult and rare cases, e.g. liver transplantation for an 8-month-old patient from a brain-dead donor, the first in Southeast Asia to reproduce 3D-printed titanium chest wall, and the first in the world to replace the pelvis and femur at the same time with 3D-printed bones.With its series of breakthroughs and pioneering achievements in high-tech healthcare and precision medicine, Vinmec further affirms the aspiration to elevate the position of Vietnam in the global medical field.Vinmec - A Place of Healing and Reimagining the Future.Hashtag: #Vinmec
The issuer is solely responsible for the content of this announcement.
About Vinmec Healthcare System
Vinmec is Vietnam's leading private healthcare system, with a network of 9 hospitals nationwide, developed to international standards with a focus on comprehensive, personalized, and specialty care. Its proud achievements include:
A strategic partnership with Cleveland Clinic , one of the world's top healthcare systems, enabling global clinical collaboration and access to world-class medical standards.
, one of the world's top healthcare systems, enabling global clinical collaboration and access to world-class medical standards. No.1 Healthcare Services for Foreigners in Vietnam , trusted by international residents for its high-quality care, globally trained physicians, and international-standard facilities.
, trusted by international residents for its high-quality care, globally trained physicians, and international-standard facilities. The only healthcare system in Asia honored at the Healthcare Asia Awards 2025 , receiving two prestigious accolades: Hospital Group of the Year and Technology Innovation of the Year , reinforcing its leadership in the region.
, receiving two prestigious accolades: and , reinforcing its leadership in the region. JCI-accredited , meeting the world's most rigorous standards for patient safety and healthcare quality.
, meeting the world's most rigorous standards for patient safety and healthcare quality. The first and only healthcare system in Vietnam to establish Centers of Excellence (CoEs) across four key specialties: Cardiology, Oncology, Orthopedics & Sports Medicine, and Clinical Immunology – Allergy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
3 days ago
- The Star
Brain-dead man's donated organs save three critically ill patients in Vietnam
The medical team performing the liver transplant surgery on the patient. - Photo courtesy of the 108 Military Central Hospital HANOI: The family of a 41-year-old man who died in a traffic accident saved at least three seriously ill people after agreeing to donate the man's organs. His liver donation helped save the lives of a soldier and a baby with end-stage liver failure. On Monday (June 23) afternoon, the National Organ Transplant Coordination Centre reported a brain-dead patient at E Hospital in Hanoi, who was killed in a traffic accident. The patient's family agreed to donate organs to help the other patients in need. A liver removal team from the Hanoi-based 108 Military Central Hospital quickly went to Hospital E to coordinate the liver removal surgery, and transferred the organ to the 108 Military Central Hospital at 2am on June 24. The team of doctors at the 108 Central Military Hospital performed an overnight liver transplant to prolong the life of a soldier with multifocal hepatocellular carcinoma and a background of cirrhosis due to hepatitis B, who was indicated for a liver transplant. After four hours of surgery, the transplant of part of the donor's liver was completed successfully. The liver recipient was fully awake and was transferred to the Department of Surgical Resuscitation and Organ Transplantation for continued monitoring and treatment. Meanwhile, the left lobe of the brain-dead donor's liver was donated to a child patient at Vinmec International Hospital, his heart was transferred to the Viet Duc Friendship Hospital for transplantation, and his cornea was transferred to the Central Eye Hospital. Major General and Professor Dr Le Huu Song, Director of 108 Central Military Hospital, said: 'Organ transplantation is a professional matter, but organ donation is a humane act, a story of conscience contributing to building a humane and compassionate society. "Brain-dead organ donors, to us, not only leave this life but also leave behind a part of their body to continue living, to continue contributing to another person's body. "We would like to express our gratitude for this noble act of the donor and his family." - Vietnam News/ANN
Malay Mail
5 days ago
- Malay Mail
Hong Kong Genome Institute and Global Leaders Co-organise Landmark Healthcare Event "International Genomic Medicine Symposium"
Convening Experts to Promote Hong Kong and Advance Medical Innovation International Genomic Medicine Symposium 17 November 2025, Hong Kong Charles K. Kao Auditorium, Hong Kong Science Park Time Programme Speaker 09:00 Keynote Prof Lo Chung-mau, BBS, JP Secretary for Health Hong Kong SAR Government, Hong Kong, China 09:15 Opening Ceremony Panel 1 Session Chairperson: Dr Ronald Lam, JP Director of Health Hong Kong SAR Government, Hong Kong, China 09:30 Developing Rare Disease Models in China: Service, Teaching and Research Prof Zhang Shuyang President Peking Union Medical College Hospital, China 10:00 Unraveling Molecular Pathogeneses to Enhance Patient Care and Family Well-being Prof Kym Boycott Co-Chair Lancet Commission on Rare Diseases Professor of Pediatrics University of Ottawa, Canada 10:30 Panel Discussion Panel 2 Session Chairperson: Dr Libby Lee, JP Under Secretary for Health Hong Kong SAR Government, Hong Kong, China 11:15 Insights into Rare Diseases: Focus on Inborn Errors of Metabolism Prof Roberto Giugliani Co-Chair Lancet Commission on Rare Diseases Professor of Genetics Federal University of Rio Grande do Sul, Brazil 11:45 Hong Kong Genome Project Case Sharing (1) – Unlocking the Genomics of Cardiomyopathy: A New Era in Heart Health Dr Derek Lee Hong Kong College of Physicians – Hong Kong Genome Institute Scholar Hong Kong, China 12:00 Hong Kong Genome Project Case Sharing (2) – Precision Medicine in Nephrology Dr Becky Ma Hong Kong Academy of Medicine – Hong Kong Genome Institute Scholar Hong Kong, China 12:15 Panel Discussion 12:30 Lunch Panel 3 Session Chairperson: Prof Philip Chiu Dean of Medicine The Chinese University of Hong Kong, Hong Kong, China 14:00 Revolutionising Plasma DNA Analysis in Transforming Non-invasive Testing and Cancer Detection Prof Dennis Lo, SBS, JP Vice-Chancellor and President The Chinese University of Hong Kong Board Member Hong Kong Genome Institute Hong Kong, China 14:30 Publishing at The Lancet Dr Chloe Wilson Senior Medical Editor The Lancet 15:00 Panel Discussion Panel 4 Session Chairperson: Prof Lau Chak-sing, BBS, JP Vice-President & Pro-Vice-Chancellor (Health) Dean of Medicine The University of Hong Kong Board Member Hong Kong Genome Institute Hong Kong, China 15:35 AI in Action: The Journey from Clinical Record to Personalised Treatment Prof Gareth Baynam Medical Director Rare Care Centre Perth Children's Hospital, Australia 16:05 Harnessing the Power of Electronic Healthcare Records in Scientific Research and Innovation in Genomic Medicine Prof Yong Chen Professor of Biostatistics University of Pennsylvania, USA 16:35 Panel Discussion Panel 5 Session Chairperson: To be confirmed 16:50 The Health Rights of Children and Genomic Newborn Screening Prof Bartha Knoppers Director Centre of Genomics and Policy McGill University, Canada 17:20 Hong Kong Genome Project: Advancing the Genomics Frontier Dr Brian Chung Chief Medical and Scientific Officer Hong Kong Genome Institute, Hong Kong, China 17:40 Genomics as a Catalyst for Drug Development in the Greater Bay Area Prof Aya El Helali Clinical Assistant Professor Department of Clinical Oncology, School of Clinical Medicine, The Li Ka Shing Faculty of Medicine of the University of Hong Kong, Hong Kong, China 18:00 Panel Discussion 18:15 End of Symposium (Last updated on 25 June 2025) Enquiry Hong Kong Genome Institute Website: Email: Rare Disease International Website: Email: Hong Kong Genome InstituteWebsite: [email protected] Rare Disease InternationalWebsite: [email protected] HONG KONG SAR - Media OutReach Newswire - 25 June 2025 - Genomic medicine is one of the most promising fields in today's healthcare landscape, enabling precise diagnoses, personalised treatment plans, and breakthroughs in drug development that bring new hope to patients around the world. Thewill join forces with world-renowned authorities to host the(Symposium) on 17 November 2025 (Monday). This landmark event will highlight Hong Kong's unique strengths in fostering exchange and cooperation with experts worldwide in medical research and innovation, and accelerate the application of genomic medicine to pave the way for a healthier future for Symposium marks HKGI's first collaboration withand, which is jointly led by RDI and, the world's most influential medical journal. The event will welcome local and international genomics leaders from over 20 countries and regions, including clinicians, scientists, and researchers from Mainland China, Europe, North and South America, and speakers at the Symposium will focus on key global topics such as clinical genetics, rare diseases, genomic medicine, AI, data sharing, as well as ethical and legal matters involved, facilitating in-depth discussions on the latest groundbreaking research and clinical insights. Specifically, thematic sessions will be dedicated to experience sharing by experts from Mainland China and Hong Kong. By showcasing case studies from the Hong Kong Genome Project, these exchanges will help demonstrate practical applications of personalised medicine in managing common disorders such as cardiomyopathy and kidney disease. Developments in rare diseases in Mainland China and drug development opportunities in the Guangdong-Hong Kong-Macao Greater Bay Area will also be covered, opening doors of opportunity for regional collaboration and "With the strong support from the Health Bureau of the Hong Kong SAR Government, HKGI has been working closely with the Department of Health, Hospital Authority, medical schools of local universities and various stakeholders to accelerate the development of genomic medicine in Hong Kong. In just a few years, the Institute has achieved significant milestones in medical research, clinical applications, and international collaborations. We have successfully recruited over 47,000 participants for the Hong Kong Genome Project, continuously expanding our genome database featuring the Southern Chinese population. We have also accumulated clinical application cases and established synergistic collaborative research platforms. These achievements highlight Hong Kong's strong capabilities and advantages in genomic medicine, laying a solid foundation for further collaboration with internationally recognised authorities."continued, "We are greatly honoured to partner with RDI and LCRD to organise this prestigious global event. Genomic medicine is the future of medicine with wide-ranging applications, spanning from common to rare diseases, from clinical diagnosis and personalised treatment to disease prevention and health management. This Symposium will undoubtedly serve as a critical platform for healthcare experts, academics, and researchers from around the world to exchange knowledge, fostering collaboration, and driving medical innovation, ultimately bringing immense benefits to patients in Hong Kong, Asia and beyond."The one-day Symposium is expected to attract nearly 300 industry professionals. Following the Symposium, the LCRD will hold its annual meeting in Hong Kong on 18-19 November to further discuss insights and deepen cross-regional collaboration. This will be the first time for the LCRD to host its annual meeting in Asia, highlighting Hong Kong's distinctive position in leading international medical information about the Symposium programme and speakers, please refer to the appendix. For enquiries about the Symposium, please contact HKGI ( [email protected] ) or RDI-LCRD ( [email protected] ).Hashtag: #HongKongGenomeInstitute The issuer is solely responsible for the content of this announcement. About Hong Kong Genome Institute The Hong Kong Genome Institute (HKGI), established and wholly owned by the Hong Kong SAR Government, commenced full operations in 2021. With the vision "to avail genomic medicine to all for better health and well-being" and supported by the Health Bureau, HKGI works in close collaboration with the Department of Health, Hospital Authority, medical schools of local universities and other stakeholders to accelerate the development of genomic medicine in Hong Kong along four strategic foci: integrate genomics into medicine, advance research, nurture talents and enhance public genomic literacy. As the first step towards achieving its vision, HKGI launched the Hong Kong Genome Project (HKGP) in 2021 focusing on diseases and research cohorts that would benefit from whole genome sequencing. They include undiagnosed diseases, hereditary cancers and cases related to genomics and precision health. Being the city's first large-scale genome sequencing project, HKGP serves as a catalyst to benefit patients and their families with more precise diagnosis and personalised treatment. It also aims to establish genome database of the local population, testing infrastructure and talent pool to address the healthcare needs of Hong Kong in the long run. For more information, please visit About Rare Diseases International Rare Diseases International (RDI) is the global alliance of people living with a rare disease of all nationalities across all rare diseases. RDI's mission is to be a strong common voice on behalf of rare disease patients around the world, to advocate for rare diseases as an international public health priority and to represent its members and enhance their capacities. RDI has more than 120 member organizations from 50 countries, which in turn represent rare disease patient groups in more than 150 countries worldwide. For more information, please visit About Lancet Commission on Rare Diseases The RDI-Lancet Commission on Rare Diseases (RDI-LCRD) is a new initiative dedicated to improving the lives of Persons Living with a Rare Disease (PLWRD) globally by generating evidence-informed recommendations that can be implemented in all countries. The RDI-LCRD, chaired by Dr Roberto Giugliani (Brazil) and Dr Kym Boycott (Canada) brings together 27 Commissioners from 6 continents with a broad range of expertise, perspectives and experience. The overarching goal of the RDI-LCRD is to use robust data to ignite global action that will amplify the voices of PLWRD and ensure that they are seen, heard, and cared for, no matter where they live. For more information, please visit
The Sun
11-06-2025
- The Sun
Vinmec performs its first total femoral replacement for world's youngest cancer patient
HANOI, VIETNAM - Media OutReach Newswire - 11 June 2025 - Vinmec Healthcare System has successfully performed a Total Femoral Replacement (TFR) surgery using personalized 3D printing materials for the world's youngest cancer patient. It is also the first biomedical product designed and produced entirely in Vietnam, marking a major milestone in the country's advancement in precision medicine. Refusing to Surrender to Fate In October 2022, after a minor fall, Tran Minh Duc (a boy from Ho Chi Minh City) hurt his left thigh. Believing it to be just a simple injury, his family was shocked to hear the bad news from the doctor: The boy was diagnosed with osteosarcoma - a malignant bone cancer with a tumor that had invaded his entire femur. It is typically seen in adolescents, but rare and haphazard in younger children. Given the severe prognosis, most medical facilities recommended amputation to ensure his survival or bone grafting (a conventional method). Both methods carry a high risk of rejection and infection, especially for younger children in the development stage. The flash of hope appeared when she met Prof. Dr. Tran Trung Dung - Director of the Orthopedic Council, Vinmec Healthcare System. An unprecedented approach was proposed to apply to such a young patient: replacing the entire femur with personalized 3D-printed materials that are produced in Vietnam. A 'Legendary' Surgery with Vietnamese Technologies According to Prof. Dr. Tran Trung Dung, the entire femur of Duc has been invaded by the tumor. To ensure his life, Duc's leg had to be amputated. However, different types of artificial joints available on the market are not compatible with young bodies. After various interdisciplinary case conferences including Orthopedics, Oncology, Diagnostic Imaging, Pathology, Clinical Pharmacy, etc., the Vinmec experts reached a consensus on the optimal approach - a two-phase surgery. Phase 1 (January 2024): Removing the tumor and temporarily grafting a cement bone. Phase 2 (May 2025): Replacing the entire femur with a 'customized' bone made of 3D-printed metal. On January 29, 2024, Duc underwent his first surgery - removing the entire tumor and temporarily grafting a cement bone. In May 2025 when his conditions had stabilized, Duc's entire femur was replaced with a 'customized' bone made of 3D-printed metal. For the first time, 3D printing was applied to the youngest patient in the world with the collaboration between Vinmec medical professionals and VinUni's engineers. The bone's design is modular, enabling future extensions based on the child's physical development. According to MSc. Dr. Tran Duc Thanh, who was directly engaged in the surgery: 'We contacted foreign manufacturers but there was no suitable design. Self-manufacturing the equipment allows us to be proactive in treatment, it also paves the way for a new direction for Vietnamese medicine.' Prof. Dr. Tran Trung Dung added: 'The 4-hour surgery was a success. Duc recovered quickly without any complications, now he is able to walk with the support of physical therapy. The surgery represented a breakthrough in complex techniques and the evidence for sound collaboration in the multidisciplinary medical team. Both the life and limb of the child were kept intact.' Vinmec - Pioneering in Vietnam's Personalized Precision Medicine Once at risk of amputation and life-long dependence, Minh Duc is now able to walk on his own feet, supported by physical therapy without any complications of infection or transplant rejection. Every step Duc takes is a testament to precision medicine, advanced technologies, and the unwavering love of his mother. 'When my son stood up, I was trembling with joy. He has been unable to walk for nearly two years. Now he did it. I just hope that he will be capable of riding a bike and playing football like his peers...' - Ms. Hoang said in tears. Prof. Dr. Tran Trung Dung also shared his emotions: 'We believe that modern medicine and compassion should go side by side. Duc is not just a special patient, his case represents a story of determination, maternal love, and the faith that the impossible can become possible if we never give up.' Vinmec is the first Vietnamese healthcare system that applies personalized 3D printing in the treatment of musculoskeletal conditions. Instead of using standardized equipment, Vinmec uses CT and MRI data in the design of artificial joints and bones tailored to each patient to optimize motor functions, enhance precision, and reduce the recovery period. To date, Vinmec has achieved successes in many difficult and rare cases, e.g. liver transplantation for an 8-month-old patient from a brain-dead donor, the first in Southeast Asia to reproduce 3D-printed titanium chest wall, and the first in the world to replace the pelvis and femur at the same time with 3D-printed bones. With its series of breakthroughs and pioneering achievements in high-tech healthcare and precision medicine, Vinmec further affirms the aspiration to elevate the position of Vietnam in the global medical field. Vinmec - A Place of Healing and Reimagining the Future.
